How MedTech Executives Are Responding to New Economic, Public Policy, and Cost-Containment Pressures

STUDY RESULTS

01 December 2010
Introduction

The “MedTech” industry is facing unprecedented pressures and uncertainty due to macroeconomic, public policy, and regulatory changes

- Recession
- Healthcare cost-containment pressures
- Regulatory and enforcement efforts
- Healthcare reform
study Overview

During 2010 PRTM conducted a study to capture the thinking of MedTech industry leaders on major policy, regulatory, and macroeconomic changes

- Emphasis on understanding the implications for MedTech innovation

The study covered the following themes:

- Economic Downturn
- Public Policy Initiatives
  - Expanded Health Care Insurance Coverage
  - Device Industry Tax
  - Comparative Effectiveness Research
  - Payment Reform
- Regulatory Initiatives
  - 510(k) Reform
  - Sunshine Provision and Massachusetts Gift Ban
  - Risk Management Scrutiny
  - National Medical Device Registry
- Overall Impact
Study Participants

Nearly 100 MedTech industry leaders participated in the study...

- Representing a broad range of U.S. medical companies
- >50% of responses from executive management

Company/Business Unit Size (Annual Revenue)

- $0—Pre-commercial: 18%
- <$100M: 39%
- $100M but <$500M: 14%
- >$500M but <$1B: 7%
- >$1B: 22%

Respondent Positions

- CEO/President: 28%
- EVP/VP: 22%
- Director: 25%
- Manager: 6%
- Other: 15%
- COO/CSO: 4%
Study Participants

Study participants included:

- MedTech companies (63%) and industry service providers
- Different segments of the MedTech industry
Study Findings and Perspectives

MACROECONOMIC TRENDS
PUBLIC POLICY INITIATIVES
REGULATORY INITIATIVES
OVERALL IMPACT
The MedTech Industry Is Not Immune

Economic downturn has affected most of the industry

How has your business performed during the current economic downturn (e.g., 2009 revenue versus 2008 revenue)?

<table>
<thead>
<tr>
<th>MedTech study Population</th>
<th>10%</th>
<th>20%</th>
<th>30%</th>
<th>40%</th>
<th>50%</th>
<th>60%</th>
<th>70%</th>
<th>80%</th>
<th>90%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Significant growth (&gt;5%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23%</td>
</tr>
<tr>
<td>Slight growth (1%-5%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22%</td>
</tr>
<tr>
<td>Flat (+/- 1%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14%</td>
</tr>
<tr>
<td>Slight decline (1%-5%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10%</td>
</tr>
<tr>
<td>Significant decline (&gt;5%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32%</td>
</tr>
</tbody>
</table>
Capital Equipment Segments Affected Most

How has your business performed during the current economic downturn (e.g., 2009 revenue vs. 2008 revenue)?

Medical supplies and implantable segments have been less susceptible to the downturn, while medical and diagnostic equipment have fared the worst.

Medical supplies and implantable segments have been less susceptible to the downturn, while medical and diagnostic equipment have fared the worst.
Starts with Economic Impact on Care Providers

Limited care provider revenue growth and profit putting pressure on MedTech suppliers

- Reduced reimbursements
- Elective procedures delayed by consumers/patients
- Reduced endowments
- Increased MedTech supplier negotiation and competition

Economic contraction and public policy uncertainty has increased the risk of care provider capital investment

- Credit/capital lending contraction
- Capacity expansion plans delayed
- Upgrades to existing equipment scrutinized

Not just a U.S. issue
Most MedTech are Trying to Maintain Innovation

How has the economic downturn impacted your company’s investment in the following areas?

Most companies have maintained or trimmed total and internal R&D investment, even with flat or growing revenues. There has been moderate growth in R&D outsourcing and co-development.
Companies Recognize Innovation Importance

R&D has been “on the table” for cost cutting, but often behind other operational areas such as SG&A and supply chain

Innovation has been responsible for sector success and will continue to be so—most believe even more so

Multiple structural levers are being pulled to improve productivity

- Review priorities and focus on highest-value programs
- Realign organizational structure
- Assess lower performing employees
- Outsource/establish collaborations

Further opportunity for transformational levers
Study Findings and Perspectives

MACROECONOMIC TRENDS
PUBLIC POLICY INITIATIVES
REGULATORY INITIATIVES
OVERALL IMPACT
Expanded Health Care Insurance Coverage

What do you think will be the impact of expanded health care insurance coverage on the market size for your company’s products?

- Approximately 40% of respondents believe that expanded coverage will not have any impact on their market size.
- The same number expect a positive impact.

**Pie Chart**

- 34.4%: Increase
- 42.6%: No impact
- 6.6%: Decrease
- 6.6%: Significant decrease
- 9.8%: Significant increase

*Approximately 40% of respondents believe that expanded coverage will not have any impact on their market size. The same number expect a positive impact.*
Some Are Skeptical of Expanded Care Benefits

Most device users tend to be older and are already covered by Medicare

Younger, uninsured individuals already have access to critical care needs through emergency visits

Newly covered individuals, will likely be younger and healthier, with fewer needs for medical devices

Increased population coverage will put added strain on the system and could result in rationing and even more reimbursement pressure
Device Excise Tax

If a device tax is implemented, how would most medical device companies likely react?

Companies expect to absorb the device tax across all expense categories. More companies are likely to cut operating expenses or attempt to expand margins while protecting their R&D spend and profits.
This Tax Will Be Countered with Cost Reductions

For companies that have products that can more easily adjust prices, price increases will be attempted

- Negotiating higher prices with payers and providers

All will focus on cost and expense management to limit profit reduction

- Adjust organizations to support greater operational efficiencies
- Reduce product costs
  - Lower raw material costs through strategic sourcing and supplier management
  - Design for Cost
  - More efficient and cost-effective manufacturing processes

Tax minimization strategies may also be employed
Comparative Effectiveness Research

What would be the impact of proposed comparative clinical effectiveness research activities on the following?

- Pricing of products that demonstrate superior comparative effectiveness
- Development cost/timelines
- Ability to obtain payor coverage/reimbursement
- Your company’s ability to innovate
- Development of “me too” products

*Increased comparative research is expected to support price premiums, drive higher development costs/timelines, and curtail investment in “me too” products.*
Significant Trial Investment With Implications

Greater R&D investment needs for each new product
- New data requirements to support efficacy comparisons and economic value
- Ability to demand price premium for superior products

Concern that comparative research may drive product use and reimbursement decisions based on economics over health benefits

Potential for improved innovation—improved care
- Better understanding of current and emerging standard of care and competitive offerings
- Greater focus on differentiation and “step” improvements in benefits
- New types of innovations that address the overall care value chain rather than point-solution products

Potential to inhibit incremental innovation
- Increased investment per offering could mean less offerings to market
- Many “big” innovations are the result of many preceding “incremental” innovations
Payment Reforms

What would be the likely impact of different payment models on each of the following criteria (relative to the current fee-for-service model)?

<table>
<thead>
<tr>
<th>Payment reform models</th>
<th>Positive Impact</th>
<th>Negative Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pay for performance</td>
<td>Price of existing devices</td>
<td>Sales volume of existing devices</td>
</tr>
<tr>
<td>Episode-based payments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accountable care organization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical home</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

New payment models may negatively affect pricing and sales of existing medical devices, while driving innovation and evidence-based medicine.
Reimbursement Change Will Guide New Innovation

Care providers will be held more accountable and will demand solutions that help them and their patients

- Increasing pressure on the prices and sales volume of existing products
- Need to align solutions to new stakeholder motivations and behavioral changes under new payment and care delivery models

Opportunity to develop products that are better aligned with new care models

- Greater focus on disease prevention and early detection
- Deliver better care quality, outcomes, and cost
- Improve provider productivity
- Accelerate procedure and recovery times
- Enable greater role of lower cost resources in care delivery
Study Findings and Perspectives

MACROECONOMIC TRENDS
PUBLIC POLICY INITIATIVES
REGULATORY INITIATIVES
OVERALL IMPACT
510(k) Reform

Is the current 510(k) process adequate to support FDA’s mission to protect and promote public health?

- Agree 53%
- Disagree 20%
- Strongly agree 15%
- Strongly disagree 3%
- No opinion 9%

Are you concerned about the impact of 510(k) reform on the following?

- Approval times
- Development costs/timelines
- Regulatory submission requirements
- Medical device innovation
- Submission fees

Nearly two-thirds of respondents believe the FDA’s 510(k) approval process is adequate. Most are concerned about the impact on R&D cost and innovation in general.
510(k) Reform Could Hurt Innovation

The intent of 510(k) reform is to help ensure patient safety

- Some believe that the process is a “rubber stamp” and can lead to company abuse

Industry advocates highlight that there have been few issues with the current system

- Current system allows the FDA to ask for more information, if concerned

Many believe that current 510(k) allows MedTech to quickly respond to patient needs and helps to drive innovation

- Incremental innovations serve as basis for step-changes in innovation
- R&D / regulatory cost and time is commensurate with product type and risk

Given that 90%+ devices go to market with 510(k) approval the potential impact is large
Physician Payment Sunshine Provision/Gift Ban

How would you characterize the potential impact of the Sunshine Provision and Massachusetts “Gift Ban” on the ability of medical device companies in the following areas?

- Medical device innovation: More than 70% of respondents believe these provisions will have a negative impact on innovation-related areas.
- Commercializing new products
- Understanding physician needs
- Compliance costs
- Conducting clinical trials

Note: Size of bubble indicated number of responses.

More than 70% of respondents believe these provisions will have a negative impact on innovation-related areas.
MedTech Companies Rely on Physician Support

Companies that regularly collaborate with physicians in their innovation process are most affected

- Disclosure of physician payments and associated transparency could hinder collaboration
- Orthopedics, cardiovascular, imaging, and many others regularly work closely with physicians and do not feel they can innovate without this dimension
- Critical to understanding patient and physician needs and creates incentives to improve standard of care

Companies will need to adjust their operating mechanisms to protect themselves against potential situations and regulatory scrutiny and to comply with reporting requirements
Risk Management Scrutiny

Are your company’s risk management practices adequate in light of FDA’s increased scrutiny?

How would you describe the impact of increased scrutiny around risk management processes on the following:

- Competitive advantage derived from safer and higher quality products
- Product safety
- Medical device innovation
- Development cost/timelines

Increased risk management scrutiny will drive product safety/quality, but may inhibit MedTech innovation and increase development costs/timelines.
Improved Device Safety with Increased Cost

Enhanced risk assessment and management practices will contribute to better definition of customer needs and context

- Doing this work productively will be critical to controlling development costs and getting innovations to market in a timely manner

Increased FDA scrutiny creates added compliance risk for MedTech companies

Many companies are currently refining their risk management practices to ensure product safety, quality and compliance

- Risk analysis, risk mitigation, risk monitoring
- Application of risk management process throughout product lifecycle
National Medical Device Registry

Do you agree with the proposed creation of a National Medical Device Registry (NMDR)?

- **Agree** 45%
- **Strongly agree** 7%
- **Disagree** 21%
- **Strongly disagree** 7%
- **No opinion** 20%

Do you agree that the data in the registry will be useful to your company from an R&D/innovation standpoint?

- **Agree** 47%
- **Strongly agree** 18%
- **Disagree** 14%
- **Strongly disagree** 5%
- **No opinion** 16%

Most respondents agree with the creation of the NMDR and expect it to provide useful data to support R&D/innovation.
Device Registry Implications

The Department of HHS will work with the FDA, CMS, Office of HIT, and Office of Veterans Affairs to define regulations for the establishment and operation of the Device registry by March 2013

- The regulation will include devices sold after March 2010 and may include select devices sold prior to March 2010

Device manufacturers will be required to submit information to the registry including the type, model, serial number, unique device identifier, and other TBD information for Class II and III devices

- FDA is leading an initiative to design and implement a Unique Device Identifier system

Device companies need to take an active role in the shaping of the Registry and its associated regulations

Device companies need to define strategies to make meaningful use of the new public information becoming available
Study Findings and Perspectives

MACROECONOMIC TRENDS
PUBLIC POLICY INITIATIVES
REGULATORY INITIATIVES
OVERALL IMPACT
Priorities For MedTech Companies

Which of the following policy and regulatory changes do you believe will have the greatest negative impact on innovation (select top three)?

- Device tax
- 501(k) reform
- Gift ban/sunshine provision
- Payment reform
- Comparative effectiveness research
- Increased vigilance around risk management
- National medical device registry

Respondents fear that the device tax and 510(k) reform will have the greatest negative impact on MedTech innovation.
U.S. Changes Lead to Global Attractiveness?

Do the uncertainties resulting from economic, public policy, and regulatory changes in the U.S. make it more attractive to do business in other countries?

If so, which of the following activities are likely to move to other countries?

- Initial product launch
- Initial regulatory filings
- Manufacturing
- Physician collaboration
- Research and development

The U.S. environment is making it more attractive to do business abroad—primarily new product filings and launches and manufacturing.
MedTech Company Response
Taking Advantage of Market Change…

**Industry Dynamics**
- U.S. Health Care Reform
- Global Recession and Credit Constraints
- Increasing Regulatory Scrutiny and New Policy
- Emerging Technologies
- Emerging Market Opportunities and Global Competition

**Change in Strategy**
- New Solutions and Business Models
- Global Target Market Emphasis and Strategies
- Company Value-Chain Focus

How will your company take advantage of this change and reposition itself for success?
Offering New and More Complete Solutions

New business model and product strategies to address new provider and reimbursement organization needs

Consider emerging care models (i.e., home care, remote Dx, etc.)
Lead in improvement of overall cost effective patient care lifecycle
Change the basis of competition for your industry!

Globalization in Driving New Revenue Growth

Increased emphasis on establishing global presence and driving growth in established and emerging markets

U.S. policies may increase urgency in establishing new global growth

Each market requires its own strategy aligned with the local healthcare system structure and competitive environment—“one size does not fit all”
Open Innovation to Support New Strategies

Source: Prof. Henry Chesbrough, UC Berkeley.
To Execute Companies Need to Change Operations

All operational value chains may need to be realigned to meet new offering, market, and cost structure requirements.
Key Operational Changes to Consider

New innovation model

- Enhance customer needs understanding capabilities to address changing market across all stakeholders
- Enhance business and product strategy capability to move beyond the traditional recipe for success
- Practices and skills in defining more cost-effective products and services
- Business development and collaboration structure, skills, and process to support open innovation acquisitions, licensing, and collaboration
- Establishment/adjustment of global innovation/R&D footprint to take advantage of global talent and address local market needs
- Clinical, regulatory, reimbursement organization skills and practices in comparative effectiveness, global health economics
- Enhance risk management throughout product lifecycle
- Adjust practices and capacity for physician payment disclosures and monitoring
Key Operational Changes to Consider

Supply chain model

- Review establishing lower-cost-country operations particularly if supports global expansion in addition to improved cost structure
- Review, consolidate, restructure supply chain asset network to improve cost structure and utilization
- Consider outsourcing for non-core operations that can be competitively sourced to improve cost, flexibility, and market expansion objectives
- Supply chain network and strategy needs to align and support changes in Innovation model, sales model, and service models

Customer experience model

- Enhance “customer” definition to more broadly include patients, providers, payers, regulatory bodies, and other value chain participants/partners
- Enhance focus on overall customer experience in Innovation
- Align sales and service organizations and processes to support new business models and customer experience expectations